Accounting Reports Accounting Treatment Merger Financial Statement Presentation
Accrued Liabilities Accuracy Financial Reports Other Public Communications
Actions Violate Antitrust Laws Additional Issuances Shares Blank Check Preferred Stock Future
Adopted 2009 Adopted Pursuant 906 Sarbanes-oxley Act 2002
Agreement Alcohol Drugs
Amendment Employment Agreement Amendment Employment Agreements Incentive Stock Option
Amendment Incentive Stock Option Agreement Announces Conference Call 2009
Annual Financial Statements Audit Assignment
Atents Audit Committee
Audit Committee Pre-approval Process Ayo Oundation Edical Ducation Esearch
Basic Diluted Loss Per Share Basis Presentation
Basis Presentation Going Concern Basis Presentation Summary Significant Accounting Policies
Beneficial Ownership Reporting Compliance Berkeley Calif 2008 Prnewswire-firstcall Nile Therapeutics Inc Otc
Board Committees Meetings Board Director
Business Development Cannot Assure Continue Meet Nasdaq Listing Requirements
Cash Bonus Payments Performance Stock Option Vesting Cash Equivalents
Cash Flow Cd-np
Certain Definitions Certain Fees
Certain Interlocking Relationships Between Affiliates River Group Holdings Certificate Signatory
Certification Certification Chief Executive Officer
Certification Chief Financial Officer Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act
Changes Independent Registered Public Accounting Firm Changes Internal Control Over Financial Reporting
Clinical Trials Cd-np Cu-np Product Candidates Future Not Code Business Conduct Ethics
Commitments Contingencies Committees Meetings Board Directors
Common Stock Common Stock Considered Penny
Communications Board Directors Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Directors
Competition Competition Fair Dealing
Compliance Antitrust Laws Compliance Insider Trading Laws
Compliance Laws Regulations Compliance Regulation
Comprehensive Loss Concentration Credit Risk
Conclusion Confidential Information
Consent Independent Registered Public Accounting Firm Contact
Contractual Obligations Controlled Current Directors Officers Principal Stockholders
Convertible Other Notes Payable Corporate Opportunities
Critical Accounting Policies Critical Accounting Policies Estimates
Cu-np Daron Evans Chief Financial Officer
Delays Commencement Enrollment Completion Clinical Testing Result Increased Description Business
Description Merger Private Placement Offering Description Property
Descrption Development Commercialization
Developments Competitors Render Products Technologies Obsolete Non-competitive Difficult Costly Protect Proprietary Rights Not Able Ensure
Director Nominees Director Qualifications
Directors Compensation Benefits Disclosure Conflicts Interest
Disclosure Schedules Dividends
Documents Incorporated Reference Drug Approval Process
Drug-development Program Depends Third-party Researchers Outside Control Each Product Candidates Early Stage Development
Echnology Icense Greement Effects Blood Pressure
Effects Hemodynamics Effects Renal Function
Employees Employment Practices
Ensure Representation Annual Meeting Please Sign Date Return Enter Strategic Partnerships Required Relinquish Important Rights Control
Estimates Even Product Candidates Receive Regulatory Approval Still Face
Even Product Candidates Receive Regulatory Approval United States Exact Name Registrant Specified Charter
Executive Management Executive Officers
Exhibits Expect Stock Price Fluctuate Significantly Not Able Resell
Expense Advances Experience Intense Competition Respect Existing Future Product Candidates
Experience Selling Marketing Distributing Products Internal Capability Unable Explanatory
Exposed Liability Claims Associated Hazardous Materials Chemicals Face Potential Product Liability Exposure Successful Claims Brought
Fair Value Financial Instruments Fees Billed Independent Registered Public Accounting Firm
Financial Results Financial Statements Index
Financings Following Definitions Certain Technical Terms Used Report Commonly
Following Holding Period Registration Sec Regulations Financing Event Food Drug Cosmetic Act Interactions Administration
Foreign Corrupt Practices Act Foreign Corrupt Practices Act Other Laws Governing Business
Form 10-k Form 10-q
Form Opinion Counsel Form Warrant
Former Name Address Changed Since Last Report Forward-looking Statements
General Administrative General Provisions
Gifts Entertainment Glossary Terms
Government Regulation Grant Income
Grant Rights Harassment Discrimination
Heart Failure Held 2008
History Net Losses Expect Continue Incur Substantial Increasing Hsiao Lieu Facc Vice President Clinical Research
Identifying Potential Conflicts Interest Impairment Disposal Long-lived Assets
Inception Income Taxes
Incur Substantial Costs Result Litigation Other Proceedings Relating Indemnification
Indemnification Agreement Indemnification Agreements
Independence Board Directors Index
Index Exhibits Filed Report Inflation
Infoniletheracom Initial Consideration
Installment Remaining Options Covering 1875000 Shall Vest Based Installment Total Options Covering 375000 Shares Shall Vest
Insurance Intangible Assets Intellectual Property
Intellectual Property License Agreements Interaction Independent Auditor
Interactions Government Largely Dependent Success Product Candidates Cd-np Cu-np Cannot
Legal Proceedings Letter Chief Executive Officer
License Agreement Commitments License Agreements
Limited Operating History Base Investment Decision Expect Number Liquidity Capital Resources
Listing Maintenance Loss Per Common Share
Managements Annual Report Internal Control Over Financial Reporting Market Information
Medical Meetings Competitors
Meetings Procedures Membership
Name Registrant Specified Charter Need Substantial Additional Funding Unable Raise Capital Forced
Never Paid Dividends New Candidates
Nile Therapeutics Nile Therapeutics Announces Dosing Heart Failure Patient Phase
Nile Therapeutics Announces Focus Cd-np Acute Heart Failure Nile Therapeutics Announces Information Compliance Nasdaq Marketplace Rule
Nile Therapeutics Announces Positive Interim Data Phase Study Nile Therapeutics Announces Positive Phase Results Cd-np Selective
Nile Therapeutics Announces Positive Results Phase Safety Pharmacodynamics Nile Therapeutics Appoints Gregory Schafer Board Directors
Nile Therapeutics Appoints Pedro Granadillo Board Directors Nile Therapeutics Completes License Agreement Cu-np Rationally Designed
Nile Therapeutics Inc Nile Therapeutics Provides Update Phase Cd-np Clinical Trial
Nominating Corporate Governance Committee Nomination Director Candidates
Nominees Not Believe Inflation Had Material Impact Business Operating
Not Establish Strategic Partnerships Undertake Development Commercialization Efforts Not Successfully Manage Growth
Notice Annual Meeting Stockholders Held 2009 Ntx-99
Objectives Off -balance Sheet Arrangements
Operations Other Matters
Other Powers Responsibilities Other Stock Option Grants
Outstanding Equity Awards Year-end Overview
Part Part Other Information
Partial Assignment Patent Filing Prosecution Maintenance Following Execution Agreement Nile
Patent Rights Enforcement Patents
Peter Strumph Former Chief Executive Officer Plan Distribution
Policy Against Retaliation Political Contributions Activities
Post-approval Requirements Prepaid Expenses
Press Release Procedures Indemnification Expense Advances
Procedures Re-nomination Current Director Procedures Recommendation Director Nominees Stockholders
Process Identifying Evaluating Director Nominees Product Candidates
Product Candidates Receive Regulatory Approval Not Achieve Broad Product Candidates Undesirable Side Effects Cause Approved Drugs
Products Novel Alternative Technologies Therapeutic Approaches Not Been Professional Organizations Trade Associations
Property Equipment Protection Assets
Proxy Statement Pursuant Securities Exchange Act 1934 Public Communications Generally
Purpose Quarterly Financial Statements
Quarterly Period 2009 Ratification Appointment Independent Registered Public Accounting Firm
Recent Turmoil Financial Markets Global Recession Adversely Affected Recently Issued Accounting Pronouncements
Recently Issued Accounting Standards Recitals
Reclassifications Recommendation
Records Regarding Forward Looking Statements
Related Parties Related Party Transactions
Relationships Competitors Relationships Suppliers
Rely Exclusively Parties Formulate Manufacture Product Candidates Rely Key Executive Officers Scientific Medical Advisors Whose
Remainder Page Intentionally Left Blank Remainder Page Left Intentionally Blank
Report Report Audit Committee
Report Independent Registered Public Accounting Firm Reporting Violations Code
Representations Warranties Indemnification Required Implement Additional Finance Accounting Systems Procedures Controls
Requirements License Agreements Not Met Suffer Significant Harm Research Development
Research Development Expenses Research Development Expenses Accruals
Research Development Plan Restricted Cash
Results Earlier Clinical Trials Not Necessarily Predictive Future Results Operations
Results Operations 2008 Compared 2007 Safe Harbor Paragraph Forward-looking Statements
Safe Harbor Statement San Francisco 2009
San Francisco California San Francisco California 94104
Sansome Street Savings Plan
Sec Reports Securities Authorized Issuance Equity Compensation Plans
Securities Exchange Act 1934 Securities Registered Pursuant Act
Seeking Help Seeking Help Information
Selling Stockholder Questionnaire Services Agreement
Services Agreement River Consulting Signature Pages Follow
Signatures Solicitation Proxies
Stock-based Compensation Stockholder Proposals
Stockholders Study
Subscription Subsequent Events
Summary Balance Sheet Data Summary Compensation Table
Table Contents Term Termination
Termination Cessation Development Nile Agrees Notify Mayo Within Trade Secrets Know-how Other Proprietary Information Disclosed Value
Transactions Affiliates Employees Transactions Related Persons
Unable Hire Additional Qualified Personnel Ability Grow Business Vesting Schedule
Violence Prevention Weapons Vote Required
Waivers Code Warrant Grant
Warrants Wire Instructions
Year-end Summary 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki